The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors.
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Honoraria - Genentech
Research Funding - Amgen; Novartis; Pfizer
George A. Fisher
No relevant relationships to disclose
Al B. Benson
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Jennifer L. Malin
No relevant relationships to disclose
Lowell Brian Anthony
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Amgen; Lilly; Novartis; Pfizer
Research Funding - ImClone Systems; Novartis
Bulent Arslan
No relevant relationships to disclose
John F. Gibbs
No relevant relationships to disclose
Edward Greeno
No relevant relationships to disclose
Renuka V. Iyer
Research Funding - Pfizer
M. K. Kim
No relevant relationships to disclose
W. Maples
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Edward M. Wolin
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Dasha Cherepanov
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Michael S. Broder
Consultant or Advisory Role - Novartis
Research Funding - Novartis